Chemical formula: C₁₇H₁₈N₆ Molecular mass: 306.365 g/mol PubChem compound: 25126798
Ruxolitinib is a selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2 (IC50 values of 3.3 nM and 2.8 nM for JAK1 and JAK2 enzymes, respectively). These mediate the signalling of a number of cytokines and growth factors that are important for haematopoiesis and immune function. Ruxolitinib inhibits cytokine-induced STAT3 phosphorylation in whole blood from healthy subjects, MF patients and PV patients.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| D11AH09 | D Dermatologicals → D11 Other dermatological preparations → D11A Other dermatological preparations → D11AH Agents for dermatitis, excluding corticosteroids | |
| L01EJ01 | Ruxolitinib | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EJ Janus-associated kinase (JAK) inhibitors |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| JAKAVI Tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Ruxolitinib is an active ingredient of these brands:
Australia (AU)
Brazil (BR)
Canada (CA)
Cyprus (CY)
Ecuador (EC)
Finland (FI)
Hong Kong (HK)
Israel (IL)
Italy (IT)Japan (JP)
Netherlands (NL)
New Zealand (NZ)
Poland (PL)
Romania (RO)
Singapore (SG)
Spain (ES)
Tunisia (TN)
Turkey (TR)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
